Top in allergy/asthma: Neffy epinephrine nasal spray; pet allergy management

ARS Pharma recently announced that the FDA will likely rule on a new drug application for the company’s neffy epinephrine nasal spray — designed to treat type 1 allergic reactions such as anaphylaxis — by Oct. 2.

In September 2023, the FDA asked ARS Pharma to further study the effects of repeated doses of neffy on patients with nasal allergen challenge conditions. The company said it has finished its clinical study and reported that the results were similar to or greater than those of intramuscular injection. It was the top story in allergy/asthma last week.

Another top story was about advancements in component testing and treatments for pet allergies that make it possible for people to live with pets and effectively manage their symptoms.

“Improved diagnostics have really improved satisfaction among patients,” Gary Falcetano, PA, U.S. scientific affairs manager at Thermo Fisher Scientific, told Healio. “They have better insight into their disease.”

Read these and more top stories in allergy/asthma below:

ARS Pharma submits response letter to FDA after further nasal epinephrine study

ARS Pharma has submitted a complete response letter to the FDA as it seeks approval for its neffy epinephrine nasal spray, which is designed to treat type I allergic reactions such as anaphylaxis, according to a company press release. Read more.

Component-based diagnosis in pet allergy improves treatment plans

Precise diagnoses that target specific dog and cat allergens can improve treatment and enable people with pet allergies to spend long, happy lives together with their furry family members, Falcetano told Healio. Read more.

Delay for allergy skin testing unnecessary after anaphylactic reaction to food

The need for a delay in skin prick testing for food allergy following an anaphylaxis reaction might be unwarranted, according to a study. Read more.

Nonspecialist health care professionals able to remove incorrect penicillin allergy labels

Nonallergy health care professionals can safely perform direct oral penicillin challenges to delabel low-risk patients, according to a study. Read more.

Genetics-first approach encouraged in diagnosing primary immune regulatory disorders

Genetic testing can provide answers about children who may have primary immunodeficiencies when antibody and cell testing meet their limits, according to a speaker. Read more.